Please try another search
| Name | Net % | Long % | Short % |
|---|---|---|---|
| Cash | 3.240 | 3.800 | 0.560 |
| Shares | 96.760 | 96.760 | 0.000 |
| Ratios | Value | Category Average |
|---|---|---|
| P/E Ratio | 12.225 | 18.099 |
| Price to Book | 2.882 | 3.979 |
| Price to Sales | 4.302 | 4.864 |
| Price to Cash Flow | 8.169 | 13.917 |
| Dividend Yield | 0.316 | 0.505 |
| 5 Years Earnings Growth | 1.839 | 8.414 |
Number of long holdings: 36
Number of short holdings: 17
| Name | ISIN | Weight % | Last | Change % | |
|---|---|---|---|---|---|
| Ionis Pharma | US4622221004 | 9.71 | 74.68 | +2.47% | |
| Biogen | US09062X1037 | 9.29 | 153.43 | +2.75% | |
| Crispr Therapeutics | CH0334081137 | 5.54 | 56.99 | +1.03% | |
| Alnylam | US02043Q1076 | 5.13 | 434.56 | +2.62% | |
| Swedish Orphan Biovitrum | SE0000872095 | 4.52 | 326.20 | -0.18% | |
| Jazz Pharma | IE00B4Q5ZN47 | 4.44 | 137.22 | -0.44% | |
| Editas Medicine | US28106W1036 | 4.31 | 2.78 | 0.00% | |
| Alkermes Plc | IE00B56GVS15 | 4.28 | 31.07 | +2.24% | |
| Prime Medicine | US74168J1016 | 4.23 | 4.400 | +2.33% | |
| Exelixis | US30161Q1040 | 4.04 | 40.37 | +6.52% |
| Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
|---|---|---|---|---|---|---|
| Selectra J Lamarck Biotech Class B | 77.09M | 19.68 | -6.80 | 2.90 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review